N-isobutyl-propanediyldiamine | 57957-09-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-isobutyl-propanediyldiamine
• 英文别名: N-Isobutyl-propandiyldiamin；N~1~-(2-Methylpropyl)propane-1,3-diamine；N'-(2-methylpropyl)propane-1,3-diamine
• CAS: 57957-09-2
• 化学式: C₇H₁₈N₂
• 分子量: 130.233
• InChiKey: MBUAMOKJRSMXKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  38
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-氯-6-甲氧基-2-甲基喹啉 、 N-isobutyl-propanediyldiamine 生成 N-isobutyl-N'-(6-methoxy-2-methyl-[4]quinolyl)-propanediyldiamine
  参考文献：
  名称：

  一些喹诺定和3-甲基喹啉衍生物。

  摘要：

  DOI：

  10.1021/ja01171a530
• 作为产物：
  描述：

  3-异丁基氨基-丙腈 在 乙醇 、 氨 、 镍 作用下， 100.0 ℃ 、10.3 MPa 条件下， 生成 N-isobutyl-propanediyldiamine
  参考文献：
  名称：

  喹啉; 一些4-氨基喹啉衍生物。

  摘要：

  DOI：

  10.1021/ja01192a030

文献信息

• 12-EPI PLEUROMUTILINS
  申请人：NABRIVA THERAPEUTICS AG

  公开号：US20160332963A1

  公开（公告）日：2016-11-17

  A compound selected from 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-sulfanyl)-acetyl]-12-epi-mutilins, or 14-O-[((Alkyl-, cycloalkyl-, heterocycloalkyl-, heteoroaryl-, or aryl)-oxy)-acetyl]-12-epi-mutilins, wherein 12-epi-mutilin is characterized in that the mutilin ring at position 12 is substituted by two substituents, the first substituent at position 12 of the mutilin ring is a methyl group which methyl group has the inverse stereochemistry compared with the stereochemistry of the methyl group at position 12 of the naturally occurring pleuromutilin ring, the second substituent at position 12 of the mutilin ring is a hydrocarbon group comprising at least one nitrogen atom and all other substituents of the mutilin ring having the same stereochemistry compared with the stereochemistry of the substituents at the corresponding positions in the naturally occurring pleuromutilin ring; optionally in the form of a salt and/or solvate, wherein the naturally occurring pleuromutilin is of formula processes for the preparation of such compounds and their use as pharmaceuticals.

  从14-O-[((烷基、环烷基、杂环烷基、杂环芳基或芳基)-硫基)-乙酰基]-12-epi-木替林，或14-O-[((烷基、环烷基、杂环烷基、杂环芳基或芳基)-氧基)-乙酰基]-12-epi-木替林中选择的一种化合物，其中12-epi-木替林的特征在于木替林环在位置12被两个取代基取代，木替林环在位置12的第一个取代基是一个甲基基团，该甲基基团的立体化学与天然存在的普鲁木替林环在位置12的甲基基团的立体化学相反，木替林环在位置12的第二个取代基是一个含有至少一个氮原子的碳氢基团，木替林环的所有其他取代基与天然存在的普鲁木替林环中相应位置的取代基的立体化学相同；可选地以盐和/或溶剂的形式存在，其中天然存在的普鲁木替林的化学式为 制备这类化合物的方法以及它们作为药物的用途。
• [EN] CYCLIC PEPTIDE ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES PEPTIDIQUES CYCLIQUES
  申请人：GENENTECH INC

  公开号：WO2020185999A1

  公开（公告）日：2020-09-17

  Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

  本发明提供了抗菌化合物，其中在某些实施例中，这些化合物具有广谱生物活性。在各种实施例中，这些化合物通过抑制细菌中的关键蛋白质——脂蛋白信号肽酶II（LspA）发挥作用。还提供了使用本发明所述化合物的药物组合物和治疗方法。
• AMINOALCOHOL LIPIDOIDS AND USES THEREOF
  申请人：Mahon Kerry Peter

  公开号：US20110293703A1

  公开（公告）日：2011-12-01

  Aminoalcohol lipidoids are prepared by reacting an amine with an epoxide-terminated compound are described. Methods of preparing aminoalcohol lipidoids from commercially available starting materials are also provided. Aminoalcohol lipidoids may be prepared from racemic or stereochemically pure epoxides. Aminoalcohol lipidoids or salts forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems. Given the amino moiety of these aminoalcohol lipidoid compounds, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive lipidoids and polynucleotide have been prepared. The inventive lipidoids may also be used in preparing microparticles for drug delivery. They are particularly useful in delivering labile agents given their ability to buffer the pH of their surroundings.

  本文描述了通过将胺与环氧末端化合物反应制备氨基醇脂质体的方法。还提供了从商业起始材料制备氨基醇脂质体的方法。氨基醇脂质体可以从外消旋或立体化学纯的环氧化合物制备。氨基醇脂质体或其盐形式最好是可生物降解和生物相容的，并可用于各种药物输送系统。鉴于这些氨基醇脂质体化合物的氨基基团，它们特别适用于多核苷酸的输送。已经制备了包含创新脂质体和多核苷酸的复合物、胶束、脂质体或粒子。创新脂质体也可以用于制备药物输送的微粒。鉴于它们能够缓冲其周围环境的pH值，它们在输送不稳定剂方面特别有用。
• Method and compositions for treating HIV infections
  申请人：Purdue Research Foundation

  公开号：EP2491785A1

  公开（公告）日：2012-08-29

  Described herein are compounds and compositions that are useful in the treatment of AIDS, and AIDS-related diseases. In addition, compounds are described herein that are both a protease dimerization and a protease inhibitor.

  本文描述了可用于治疗艾滋病和艾滋病相关疾病的化合物和组合物。此外，本文还描述了既是蛋白酶二聚体又是蛋白酶抑制剂的化合物。
• MODIFIED BLOCK COPOLYMER, METHOD FOR PRODUCING MODIFIED BLOCK COPOLYMER, AND RESIN COMPOSITION
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：EP3623398A1

  公开（公告）日：2020-03-18

  A modified block copolymer according to the present invention is a modified block copolymer comprising a polymer block comprising a vinyl aromatic compound as a main constituent (A), a polymer block comprising a conjugate diene compound as a main constituent (B), and an atomic group having NHx (x = 0 to 2) (C). In the modified block copolymer, the polymer block comprising a conjugate diene compound as a main constituent (B) is a hydrogenated product, the atomic group having NHx (x = 0 to 2) (C) is contained in a side chain, and a compound forming the atomic group having NHx (x = 0 to 2) (C) satisfies the following condition: Condition: when the compound forming the atomic group having NHx (x = 0 to 2) (C) is reacted with a maleic anhydride-modified group in a maleic anhydride-modified block copolymer, a MFR value at 230°C under a load of 2.16 kg of the modified block copolymer after the reaction is 0.1 times or more a MFR value at 230°C under a load of 2.16 kg of the maleic anhydride-modified block copolymer before the reaction.

  根据本发明，改性嵌段共聚物是一种改性嵌段共聚物，包括以乙烯基芳香族化合物为主要成分的聚合物嵌段（A）、以共轭二烯化合物为主要成分的聚合物嵌段（B）和具有 NHx（x = 0 至 2）的原子团（C）。在改性嵌段聚合物中，由共轭二烯化合物作为主要成分（B）的聚合物嵌段是氢化产物，具有 NHx（x = 0 至 2）（C）的原子团包含在侧链中，形成具有 NHx（x = 0 至 2）（C）的原子团的化合物满足以下条件： 条件：当形成具有 NHx（x = 0 至 2）(C)的原子团的化合物与马来酸酐改性嵌段共聚物中的马来酸酐改性基团反应时，反应后在 230℃、负载 2.16 千克改性嵌段共聚物时的 MFR 值是反应前在 230℃、负载 2.16 千克马来酸酐改性嵌段共聚物时的 MFR 值的 0.1 倍或以上。